We then retrospectively enrolled 216 MM patients treated with novel agents as induction therapy followed by autologous stem cell transplantation (ASCT) at our center over the past 10 years, with longitudinal monitoring of MAGE-C1/CT7 levels in the bone marrow. This evidence concerns the gene MAGEC1 and Miyoshi myopathy.